Table 1 Baseline characteristics of patients with recurrent pancreatic ductal adenocarcinoma
Characteristic | *Overall N = 211 | No Therapy N = 71 | Non-Standard Combination N = 47 | Single Agent N = 19 | Standard Combination N = 74 | P-value |
|---|---|---|---|---|---|---|
Age at diagnosis (years) Median (range) | 64.3 (57.2, 70.6) | 67.9 (36.4, 87.2) | 64.2 (45.7, 82.7) | 64.6 (44.2, 88.9) | 61.7 (31.6, 83.9) | .00791 |
Gender | .0675 | |||||
F | 96 (45%) | 38 (54%) | 19 (40%) | 12 (63%) | 27 (36%) | |
M | 115 (55%) | 33 (46%) | 28 (60%) | 7 (37%) | 47 (64%) | |
Race | .7211 | |||||
Asian | 1 (0%) | 0 | 0 | 0 | 1 (1%) | |
Black or African American | 9 (4%) | 3 (4%) | 1 (2%) | 2 (11%) | 3 (4%) | |
Other | 1 (0%) | 1 (1%) | 0 | 0 | 0 | |
White | 200 (95%) | 67 (94%) | 46 (98%) | 17 (89%) | 70 (95%) | |
Stage | .0293 | |||||
I | 12 (6%) | 2 (3%) | 4 (9%) | 2 (11%) | 4 (6%) | |
IIA | 27 (13%) | 6 (8%) | 6 (13%) | 3 (16%) | 12 (17%) | |
IIB | 166 (80%) | 63 (89%) | 36 (78%) | 12 (63%) | 55 (76%) | |
III | 3 (1%) | 0 | 0 | 2 (11%) | 1 (1%) | |
Comorbid Conditions | .6393 | |||||
No | 133 (63%) | 43 (61%) | 32 (68%) | 10 (53%) | 48 (65%) | |
Yes | 78 (37%) | 28 (39%) | 15 (32%) | 9 (47%) | 26 (35%) | |
Diabetes | .3180 | |||||
No | 131 (62%) | 41 (58%) | 28 (60%) | 10 (53%) | 52 (70%) | |
Yes | 80 (38%) | 30 (42%) | 19 (40%) | 9 (47%) | 22 (30%) | |
Tumor Location | .7085 | |||||
Body | 10 (5%) | 3 (4%) | 2 (4%) | 2 (11%) | 3 (4%) | |
Head | 153 (73%) | 54 (76%) | 37 (79%) | 14 (74%) | 48 (65%) | |
Neck | 14 (7%) | 4 (6%) | 1 (2%) | 1 (5%) | 8 (11%) | |
Tail | 25 (12%) | 8 (11%) | 4 (9%) | 2 (11%) | 11 (15%) | |
Uncinate Process | 9 (4%) | 2 (3%) | 3 (6%) | 4 (5%) | ||
Margin Negative Resection | .8253 | |||||
No | 51 (24%) | 18 (26%) | 12 (26%) | 3 (16%) | 18 (24%) | |
Yes | 158 (76%) | 52 (74%) | 34 (74%) | 16 (84%) | 56 (76%) | |
Lymphovascular Invasion | .1892 | |||||
No | 67 (33%) | 18 (26%) | 13 (30%) | 5 (26%) | 31 (42%) | |
Yes | 139 (67%) | 51 (74%) | 31 (70%) | 14 (74%) | 43 (58%) | |
Perineural Invasion | .9466 | |||||
No | 29 (14%) | 9 (13%) | 7 (15%) | 2 (11%) | 11 (15%) | |
Yes | 180 (86%) | 61 (87%) | 39 (85%) | 17 (89%) | 63 (85%) | |
Recurrence Site | .8993 | |||||
Distant | 154 (73%) | 51 (72%) | 36 (77%) | 13 (68%) | 54 (74%) | |
Local | 56 (27%) | 20 (28%) | 11 (23%) | 6 (32%) | 19 (26%) | |
Perioperative Chemotherapy | .0088 | |||||
No | 41 (19%) | 21 (30%) | 2 (4%) | 4 (21%) | 14 (19%) | |
Yes | 170 (81%) | 50 (70%) | 45 (96%) | 15 (79%) | 60 (81%) | |
Radiotherapy for rPDAC | .8576 | |||||
No | 183 (89%) | 61 (87%) | 41 (89%) | 15 (94%) | 66 (90%) | |
Yes | 22 (11%) | 9 (13%) | 5 (11%) | 1 (6%) | 7 (10%) | |